Seres Therapeutics CMO Lisa von Moltke resigns effective March 14, 2025

Seres Therapeutics, Inc.

Lisa von Moltke, M.D., notified Seres of her resignation as EVP and Chief Medical Officer.
Resignation effective March 14, 2025; she accepted a CMO and Head of R&D role at a biopharma.
No successor named; search process not disclosed.
Dr. von Moltke's departure is for a role in autoimmune disease therapeutics.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Lisa von Moltke

Executive Vice President and Chief Medical Officer

MCRB · Seres Therapeutics, Inc.

Effective: 2025-03-14
Filed: February 27, 2025, 6:59 PM ET

On February 22, 2025, Lisa von Moltke, M.D. notified Seres Therapeutics, Inc. (the “Company”) of her intention to resign as the Executive Vice President and Chief Medical Officer of the Company, effective as of March 14, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Lisa von Moltke resigned as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc..

Action: resigned
Role: Executive Vice President and Chief Medical Officer

Exact text from the filing

On February 22, 2025, Lisa von Moltke, M.D. notified Seres Therapeutics, Inc. (the “Company”) of her intention to resign as the Executive Vice President and Chief Medical Officer of the Company, effective as of March 14, 2025.

View on SEC.gov

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-039256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.